OMS ElectroImmunotherapy: Preliminary Phase II data

Preliminary data from 4 evaluable patients with treatment-refractory metastatic and unresectable SCCHN in the open-label, U.S. Phase II OMS-I130 trial showed that intratumoral ImmunoPulse IL-12 increa...